Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.3 CHF | 0.00% | +5.37% | -29.26% |
Apr. 23 | Xlife Sciences Posts Higher FY23 Profit; Revenue Falls | MT |
Feb. 29 | Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 800K 882K | Sales 2025 * | - | Capitalization | 201M 222M |
---|---|---|---|---|---|
Net income 2024 * | -4M -4.41M | Net income 2025 * | - | EV / Sales 2024 * | 333 x |
Net Debt 2024 * | 65.2M 71.91M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-53.5
x | P/E ratio 2025 * |
-
| Employees | 17 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 49.77% |
1 week | +5.37% | ||
Current month | +10.31% | ||
1 month | -3.55% | ||
3 months | -23.09% | ||
6 months | -5.11% | ||
Current year | -29.26% |
Managers | Title | Age | Since |
---|---|---|---|
Oliver Baumann
CEO | Chief Executive Officer | - | 19-06-30 |
Carl von Halem
DFI | Director of Finance/CFO | - | 21-11-30 |
Alexander Zink
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Christian Faber
CMP | Compliance Officer | - | 19-09-11 |
Mark Müller
BRD | Director/Board Member | - | 18-10-24 |
Oliver Baumann
CEO | Chief Executive Officer | - | 19-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 35.3 | 0.00% | 4,795 |
24-05-08 | 35.3 | +0.86% | 9,715 |
24-05-07 | 35 | +1.45% | 1,462 |
24-05-06 | 34.5 | +2.99% | 2,847 |
24-05-03 | 33.5 | +4.69% | 3,755 |
Delayed Quote Swiss Exchange, May 10, 2024 at 11:31 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-29.26% | 222M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- XLS Stock